Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Off-time Treatment Options for Parkinson’s Disease
Margherita Fabbri, Raquel Barbosa, Olivier Rascol
Neurology and Therapy (2023) Vol. 12, Iss. 2, pp. 391-424
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Levodopa–Carbidopa–Entacapone Intestinal Gel in Advanced Parkinson Disease: A Multicenter Real-Life Experience
József Attila Szász, Adriana Octaviana Dulămea, Viorelia Constantin, et al.
American Journal of Therapeutics (2024)
Closed Access | Times Cited: 13
The Management of Parkinson’s Disease: An Overview of the Current Advancements in Drug Delivery Systems
Deepa D. Nakmode, Candace M. Day, Yunmei Song, et al.
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1503-1503
Open Access | Times Cited: 15
German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson’s disease: new spotlights on diagnostic procedures and non-pharmacological interventions
Elke Kalbe, Ann‐Kristin Folkerts, Karsten Witt, et al.
Journal of Neurology (2024) Vol. 271, Iss. 11, pp. 7330-7357
Open Access | Times Cited: 5
Rethinking the Role of Continuous Dopaminergic Stimulation in Parkinson Disease Therapy
Peter A. LeWitt
Parkinsonism & Related Disorders (2025), pp. 107354-107354
Closed Access
Ranking of treatments in network meta-analysis: incorporating minimally important differences
Tristan Curteis, Augustine Wigle, Christopher J. Michaels, et al.
BMC Medical Research Methodology (2025) Vol. 25, Iss. 1
Open Access
Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations
Thomas Koeglsperger, Emir Berberovic, Christian Dresel, et al.
Journal of Neural Transmission (2025)
Open Access
Management of freezing of gait — mechanism-based practical recommendations
Anouk Tosserams, Alfonso Fasano, Moran Gilat, et al.
Nature Reviews Neurology (2025)
Closed Access
Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review
Harmen R. Moes, Tove Henriksen, Jaroslaw Sławek, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 11, pp. 1359-1377
Open Access | Times Cited: 12
Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson’s disease
Angela M. Richmond, Kelly E. Lyons, Rajesh Pahwa
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 7, pp. 563-579
Closed Access | Times Cited: 9
Amantadine mitigates the cytotoxic and genotoxic effects of doxorubicin in SH-SY5Y cells and reduces its mutagenicity
Solange Soares, Jayne Torres de Sousa, Fernanda Brião Menezes Boaretto, et al.
Toxicology in Vitro (2024) Vol. 99, pp. 105874-105874
Closed Access | Times Cited: 3
Research progress on the protection and mechanism of active peptides in Alzheimer's disease and Parkinson's disease
Xuying Ding, Yutong Chen, Xiaojun Zhang, et al.
Neuropeptides (2024) Vol. 107, pp. 102457-102457
Closed Access | Times Cited: 2
Exploring Nanocarriers for Boosting Entacapone Bioavailability: A Journey through System Characterization and Assessment of Toxicity and Pharmacological and 2D Permeability Paybacks
Cláudia Sofia Machado, Miguel Pinto, Brandon Aguiar, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 43, pp. 58299-58312
Closed Access | Times Cited: 2
The Interplay of Mitochondrial Bioenergetics and Dopamine Agonists as an Effective Disease-Modifying Therapy for Parkinson’s Disease
Neha Neha, Iqra Mazahir, Sara Akhtar Khan, et al.
Molecular Neurobiology (2024) Vol. 61, Iss. 10, pp. 8086-8103
Closed Access | Times Cited: 1
Using Polymers as Crystal Inhibitors to Prevent the Crystallization of the Rotigotine Patch
Qiantong Liu, Xing Li, Bo Liu, et al.
Pharmaceutics (2024) Vol. 16, Iss. 5, pp. 630-630
Open Access | Times Cited: 1
Sublingual apomorphine in the treatment of Parkinson’s disease
Jan Kassubek, Wolfgang H. Jost, Johannes Schwarz
Journal of Neural Transmission (2024) Vol. 131, Iss. 10, pp. 1209-1216
Closed Access | Times Cited: 1
Nanotechnological advancement for the treatment of neurodegenerative disorders
Garima Rai, Surbhi Sharma, Aditi Singh, et al.
Journal of Dispersion Science and Technology (2024), pp. 1-19
Closed Access | Times Cited: 1
The Structural Characteristics of Compounds Interacting with the Amantadine-Sensitive Drug Transport System at the Inner Blood–Retinal Barrier
Yusuke Shinozaki, Yuma Tega, Shin‐ichi Akanuma, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 435-435
Open Access | Times Cited: 2
Safety and Efficacy of Apomorphine in the Treatment of Sleep Disorders in Parkinson’s Disease: A Systematic Review
Ziyuan Wang, Jiannan Wu, Junqiang Yan
Research Square (Research Square) (2024)
Open Access
Perspectivas Atuais sobre Terapias para a Doença de Parkinson: Uma Análise da Literatura Contemporânea
Leonardo Pereira Levada, Júlia Letícia De Souza Barbosa, Ezo Neto de Souza Ferreira, et al.
Brazilian Journal of Implantology and Health Sciences (2024) Vol. 6, Iss. 3, pp. 2397-2408
Open Access
Treating Idiopathic Parkinson’s Disease with <i>Bonoesikpungjigyeong-tang</i> : A Case Study on “Delayed On” and “Wearing Off” Phenomena after Long-term Levodopa Intake
Siyun Sung, Dabin Lee, Seongeun Huh, et al.
The Journal of Internal Korean Medicine (2024) Vol. 45, Iss. 2, pp. 219-233
Open Access
Grasping the big picture: impact analysis of screening tools for timely referral for device-aided therapies
Harmen R. Moes, Haidar S. Dafsari, Wolfgang H. Jost, et al.
Journal of Neural Transmission (2024) Vol. 131, Iss. 11, pp. 1295-1305
Open Access
When and how to refer patients for DBS
Omar Odish, Daniel de Waard
Elsevier eBooks (2024), pp. 1-8
Closed Access
Pharmacotherapy of motor symptoms in early and mid-stage Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology
Matthias Höllerhage, Jos S. Becktepe, Joseph Claßen, et al.
Journal of Neurology (2024) Vol. 271, Iss. 11, pp. 7071-7101
Open Access
Clinical Aspects and Treatment of Parkinson Disease: a Biochemical Perspective
Adnan Ayna
(2024), pp. 141-161
Closed Access
The beta-sitosterol beta-D-glucoside (BSSG) rat model of Parkinson's disease
Raafat Soliman, Nourhan S. Sultan, Hagar Mostafa Lokman, et al.
Elsevier eBooks (2024), pp. 187-201
Closed Access
Page 1 - Next Page

Scroll to top